IP Library Granted Patent US 8,394,593
Granted Patent B2
US 8,394,593 · App. 13/022,224 · Granted Mar 12, 2013

Use of an IL-12 receptor splice variant and molecular assay to quantify expression thereof

Inventors: Richard T. Robinson (Milwaukee, WI); Andrea M. Cooper (Saranac Lake, NY)
Assignee: Trudeau Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,394,593
App. No.
13/022,224
Granted
Mar 12, 2013
Kind
B2
Abstract

The present invention describes compositions for both diagnostic and therapeutic applications. In one embodiment, the present invention contemplates a vaccine formulation comprising an antigen and IL12Rβ1 isoform 2. In some embodiments, this invention relates to a method of quantifying the ratio of IL12Rβ1 transcript and a splice variant thereof in a sample, including but not limited to at the cDNA level. In other embodiments, this invention relates to a method of augmenting an immune response by administering, inhibiting and/or inducing IL12Rβ1 isoform 2.

Claims (20)

1. A method for detecting a transcript and a splice variant thereof, comprising:

a) providing:

i) a sample comprising cDNA molecules corresponding to the transcript encoding IL12Rβ1 isoform 1 and the splice variant encoding IL12Rβ1 isoform 2, at least one of said cDNA molecules not comprising a transmembrane-encoding region,

ii) a PCR primer set flanking said transmembrane-encoding region of said cDNA molecules, and

b) amplifying said cDNA with said PCR primer set so as to produce PCR products, and

c) detecting the PCR products corresponding to the cDNA molecules of said transcript encoding IL12Rβ1 isoform 1 and said splice variant encoding IL12Rβ1 isoform 2.

2. The method of claim 1 , wherein said detecting is performed with a fluorescent-conjugated primer or probe.

3. The method of claim 1 , wherein said detecting is performed by fluorescent capillary electrophoresis.

4. The method of claim 3 , wherein said fluorescent capillary electrophoresis produces first and second peaks corresponding to the labeled PCR products of the cDNA molecules of said transcript encoding IL12Rβ1 isoform 1 and said splice variant encoding IL12Rβ1 isoform 2.

5. The method of claim 4 , wherein the relative abundance of each of said peaks is determined.

6. The method of claim 1 , wherein the nucleotide sequence of the forward PCR primer is SEQ ID NO:1.

7. The method of claim 1 , wherein the nucleotide sequence of the reverse PCR primer is SEQ ID NO:2.

8. The method of claim 1 , wherein detecting the PCR products further comprises detecting the ratio of the PCR products corresponding to the cDNA molecules of said transcript encoding IL12Rβ1 isoform 1 and the splice variant encoding IL12Rβ1 isoform 2.

9. The method of claim 1 , wherein said sample is isolated from a cell.

10. The method of claim 9 , wherein said cell is a dendritic cell.

11. The method of claim 10 , wherein said cell has been exposed to a pathogen.

12. The method of claim 11 , wherein said pathogen is Mycobacterium tuberculosis .

13. A primer consisting of the nucleotide sequence of SEQ ID NO: 1.

14. A primer set comprising the primer of claim 13 and a second primer consisting of the nucleotide sequence of SEQ ID NO: 2.

15. A kit comprising the primer set of claim 14 .

Assignments (2)
CONFIRMATORY LICENSE Recorded Apr 24, 2012
From: TRUDEAU INSTITUTE, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028093/0948 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2011
From: ROBINSON, RICHARD T.; COOPER, ANDREA M.
To: TRUDEAU INSTITUTE
Reel/Frame 026528/0195 →
Continuity (2)
Provisional Application 61304025 · Feb 12, 2010
Related Publication 20110256158A1 · Oct 20, 2011